stanza
(2)
Swing Therapeutics, Inc.
Swing Therapeutics is a San Francisco digital therapeutics company building software-based treatments for chronic illness. Its flagship product, Stanza, is the first FDA-cleared prescription digital therapy for fibromyalgia, delivering acceptance and commitment therapy (ACT) through a smartphone in roughly 15 minutes a day. The company also operates Swing Care, a telehealth clinic that prescribes and supports the therapy across multiple states.
Mike Rosenbluth
Mike Rosenbluth is the Founder and CEO of Swing Therapeutics, the San Francisco-based company behind Stanza - the first FDA-authorized prescription digital therapeutic for fibromyalgia symptoms. A Stanford-trained mechanical engineer with a UC Berkeley PhD in Bioengineering, Rosenbluth spent years at McKinsey, a VC firm (Versant Ventures), and cancer diagnostics company Veracyte before founding Swing in 2019. His company's landmark PROSPER-FM Phase 3 trial results were published in The Lancet in 2024, and Swing has raised over $30 million to bring evidence-based, non-drug behavioral therapy to the estimated 4 million Americans with fibromyalgia.